Connect with NEA Clinical about your upcoming clinical trial
Request a proposal
Connect with NEA Clinical about our upcoming vacancies
Request a proposal
Connect with NEA Clinical about your upcoming clinical trial
Request a proposal
Home
Solutions
Expertise
Сontacts
Trust on conducting studies to NEA Clinical
Why Megalek
We will do our best for your study being successful
CLINICAL TRIALS IN POLAND
Poland has population of 37.9 million people and is the fifth-most populous member state of the European Union. Poland remains to be one of the largest clinical trial markets in CEE, having a share close to 20% in terms of the number of clinical trials held.
An EU member since 2004, Poland has its medical and pharmaceutical legislation harmonized with the EU. The typical timeline for receiving authorization from the regulatory authorities to conduct medicinal or device trials is 60 days.
Similarly, to other countries within the EU, Poland requires Regulatory Agency/Competent Authority (RA) and Ethics Committee (EC) approvals before the drug or device trial can start.
Health care in Poland is delivered through a publicly funded health care system, but the private sector is steadily growing as well. Every person of working age pays a compulsory insurance fee of approximately 9% of their income, which goes to the National Health Fund (NFZ). At the same time, it is sufficient for one family member to have the insurance, which is automatically applied to everyone else in the family. Retirees receive health insurance for free, students are provided with one by their universities, and the unemployed are provided by the local labor departments.
An EU member since 2004, Poland has its medical and pharmaceutical legislation harmonized with the EU. The typical timeline for receiving authorization from the regulatory authorities to conduct medicinal or device trials is 60 days.
Similarly, to other countries within the EU, Poland requires Regulatory Agency/Competent Authority (RA) and Ethics Committee (EC) approvals before the drug or device trial can start.
Health care in Poland is delivered through a publicly funded health care system, but the private sector is steadily growing as well. Every person of working age pays a compulsory insurance fee of approximately 9% of their income, which goes to the National Health Fund (NFZ). At the same time, it is sufficient for one family member to have the insurance, which is automatically applied to everyone else in the family. Retirees receive health insurance for free, students are provided with one by their universities, and the unemployed are provided by the local labor departments.
CLINICAL DEVELOPMENT SOLUTIONS OVERVIEW
CLINICAL TRIALS IN POLAND
Poland has population of 37.9 million people and is the fifth-most populous member state of the European Union. Poland remains to be one of the largest clinical trial markets in CEE, having a share close to 20% in terms of the number of clinical trials held.
An EU member since 2004, Poland has its medical and pharmaceutical legislation harmonized with the EU. The typical timeline for receiving authorization from the regulatory authorities to conduct medicinal or device trials is 60 days.
Similarly, to other countries within the EU, Poland requires Regulatory Agency/Competent Authority (RA) and Ethics Committee (EC) approvals before the drug or device trial can start.
Health care in Poland is delivered through a publicly funded health care system, but the private sector is steadily growing as well. Every person of working age pays a compulsory insurance fee of approximately 9% of their income, which goes to the National Health Fund (NFZ). At the same time, it is sufficient for one family member to have the insurance, which is automatically applied to everyone else in the family. Retirees receive health insurance for free, students are provided with one by their universities, and the unemployed are provided by the local labor departments.
An EU member since 2004, Poland has its medical and pharmaceutical legislation harmonized with the EU. The typical timeline for receiving authorization from the regulatory authorities to conduct medicinal or device trials is 60 days.
Similarly, to other countries within the EU, Poland requires Regulatory Agency/Competent Authority (RA) and Ethics Committee (EC) approvals before the drug or device trial can start.
Health care in Poland is delivered through a publicly funded health care system, but the private sector is steadily growing as well. Every person of working age pays a compulsory insurance fee of approximately 9% of their income, which goes to the National Health Fund (NFZ). At the same time, it is sufficient for one family member to have the insurance, which is automatically applied to everyone else in the family. Retirees receive health insurance for free, students are provided with one by their universities, and the unemployed are provided by the local labor departments.
Therapeutic areas:
Gastroenterology
Oncology
Allergology
Cardiovascular
Dermatology
Endocrinology
Hematology
Immunology
Pulmonary / Respiratory Diseases
Rheumatology
Nephrology
Infections and Infectious Diseases
Oncology
Allergology
Cardiovascular
Dermatology
Endocrinology
Hematology
Immunology
Pulmonary / Respiratory Diseases
Rheumatology
Nephrology
Infections and Infectious Diseases
HOSPITAL BUKOWIEC,
Kowary
Kowary
WYSOKA LAKA HOSPITAL; BUKOWIEC, Poland
UNIVERSITY HOSPITAL,
Krakow
Krakow